Hospital

Academic, community, first responder, government, and medical leaders call for better options to save lives.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

When replaced with just 6 to 7 minutes daily of light-intensity exercise or sedentary behavior, data show poorer cognitive performance.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

Relatively higher suicide risks were observed for cancer types with a poor prognosis and high symptom burden in the first 2 years after diagnosis.

Most individuals who used cannabis to manage their chronic pain reported using it in place of other pain medications, including opioids.

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

Respiratory syntactical virus burdens quality of life and can lead to long-term health outcomes.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

Based on study findings, Moderna plans to submit for regulatory approval in the first half of 2023 for mRNA-1345, a novel vaccine for respiratory syncytial virus.

Specific data and results for pembrolizumab in patients with advanced or unresectable biliary tract cancer will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Multisystem inflammatory syndrome typically presents approximately 1 month after a COVID infection, occasionally resulting in cardiac complications in previously healthy children.

The investigators observed a 96.8% S. aureus reduction in stool and a 65.4% reduction in the nose among patients who received the probiotic.

Individuals with the virus had an 81 times higher risk of dying in the first 3 weeks of infection, and that remained 5 times higher for up to 18 months, analysis shows.

Surgical embolectomy and venoarterial extracorporeal membrane oxygenation demonstrate favorable safety and efficacy profiles.

In a phase 3 trial, empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo.

Research showed that 600 hospital beds filled with patients with severe illness would be enough to reimplement (mask mandates to stop the spread of infection.

New findings reveal the previously misunderstood mechanism by which PCSK9 degrades the low-density lipoprotein receptor.

The therapeutic option is demonstrating favorable results for patients, despite the evolving nature of the SARS-CoV-2 virus.

In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.

Luke Gormley, PharmD, BCPS, discusses how pharmacists are involved in the management of inclisiran.

Enhanced care involves a pharmacy technician serving as a patient navigator who screens for health-related social needs quarterly and helps to connect patients with community resources.

Data from a recent survey reflect a resounding shift toward the role of pharmacies becoming sites for primary care.

American Heart Association scientific statement recommends rapid evaluation for transient ischemic attacks.

Independent, scheduled review of Phase 3 Mosaico clinical trial finds a lack of efficacy in preventing the infection.

An organ transplant is a known risk factor for C. difficile infection, however, data are lacking on how the infection affects those who underwent an intestinal transplant.

The findings suggest that reduced gray matter is not the cause of psychiatric illness, although it is found in regions of the brain associated with it.